Meriwether Wealth & Planning’s Neurocrine Biosciences NBIX Stock Holding History

Meriwether Wealth & Planning’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.22K	Buy	+65	New	+$10.4K	﹤0.01%	428

Other funds holding NBIX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Meriwether Wealth & Planning's NBIX Position: Q3 2026 in Review

Meriwether Wealth & Planning opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 65 shares worth $9.22K. The stake represents ﹤0.01% of the portfolio and ranks #428 among its holdings.

201 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Meriwether Wealth & Planning held 65 shares of Neurocrine Biosciences worth $9.22K as of Q3 2026.
Neurocrine Biosciences was a new Meriwether Wealth & Planning position in Q3 2026.
Neurocrine Biosciences made up ﹤0.01% of Meriwether Wealth & Planning's portfolio in Q3 2026, its #428 holding.
201 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Meriwether Wealth & Planning's 13F filing for Q3 2026, filed 13 Oct 2026.